Expression of vascular endothelial growth factor and its receptors is increased, but microvascular relaxation is impaired in patients after acute myocardial ischemia  by Xu, Xunyu et al.
V ascular endothelial growth factor (VEGF), basicfibroblast growth factor (FGF2), and other angio-
genic growth factors are involved in the development of
collateral vessels during both acute and chronic
myocardial ischemia.1-3 In addition, the administration
of exogenous angiogenic substances, such as VEGF or
FGF2, may have a role in the treatment of patients with
obstructive coronary artery disease who are not candi-
Background: Vascular endothelial growth factor, a specific endothelial mitogen,
plays an important role in myocardial angiogenesis. Previous work has demon-
strated increased expression of vascular endothelial growth factor and its recep-
tors in a rat myocardial infarction model, as well as in a pig model of chronic
ischemia. The expression of vascular endothelial growth factor and other
growth factors after acute myocardial ischemia in patients has not been exam-
ined. In this study we examined the expression of vascular endothelial growth
factor and its receptors and the responsiveness of human atrial microvessels to
vascular endothelial growth factor before and after acute ischemia.
Methods: Paired specimens of human atrial tissue were harvested before and
after atrial devascularization (ligation) in 16 patients undergoing coronary
bypass operations.
Results: The messenger RNA (reverse transcriptase–polymerase chain reac-
tion) level of vascular endothelial growth factor and vascular endothelial
growth factor receptor 1 were increased by 22.2% ± 4.2% and 30.7% ± 7.6%,
respectively (P < .05), in the ischemic specimens as compared with the control
specimens. Protein expression (Western blotting) of vascular endothelial
growth factor and that of vascular endothelial growth factor receptor 1 also
were increased significantly by 71.7% ± 27.8% and 68.2% ± 27.6%, respec-
tively (P < .05). However, both RNA and protein expressions of another vas-
cular endothelial growth factor receptor, vascular endothelial growth factor
receptor 2, and fibroblast growth factor and fibroblast growth factor receptor 1
were unchanged. Reactivity of precontracted atrial vessels was examined with
video microscopy. Vascular endothelial growth factor–induced (33.9% ± 2.4%
vs 18.3% ± 2.8% in control and ischemic vessels, respectively; P < .05),
fibroblast growth factor–induced (31.6% ± 3.2% vs 15.8% ± 4.1%, P < .05),
and substance P–induced (84.5% ± 3.7% vs 54.3% ± 9.0%, P < .05) microvas-
cular relaxations were decreased in ischemic samples and in the presence of
NGnitro-L-arginine, whereas responses to sodium nitroprusside were
unchanged (90.9% ± 2.2% vs 91.2% ± 2.0%).
Conclusions: This study suggests that acute myocardial ischemia in patients
results in increased expression of vascular endothelial growth factor but not
fibroblast growth factor and that the functional activity of vascular endothe-
lial growth factor receptors and that of other growth factors may be impaired.
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dates for coronary artery bypass operations or percuta-
neous coronary angioplasty because of diffusely dis-
eased or extremely small vessels.4 Either the perivascu-
lar or intravascular administration of growth factor
proteins produces significant improvement of perfusion
in experimental models of chronic myocardial
ischemia,5-7 and somewhat lesser degrees of benefit
have been reported in human growth factor trials.1,8-13
Reasons for this diminished effect include endothelial
dysfunction caused by hypercholesterolemia, diabetes
mellitus, or hypertension.14,15 The effect of acute
myocardial ischemia on the expression of angiogenic
growth factors VEGF and FGF2 and their respective
receptors has not been examined in patients. It was
hypothesized that expression of VEGF, FGF2, and their
receptors would be increased but that the microvascular
response (as measured by stimulated vascular relax-
ation) would be reduced because of a generalized
defect in endothelial function.
Methods
Tissue harvest. The atrial appendage was harvested from
patients undergoing cardiac operations with cardiopulmonary
bypass (CPB). A silk suture (1-0) was placed around the atri-
al appendage. After administration of heparin, a single, 2-
stage atrial cannula was placed and secured with the suture. A
piece of right atrial tissue was harvested above the cannula-
tion suture after heparinization but before cannulation (con-
trol group). The venous cannula was then secured. Care was
taken to assure that the atrial tissue above the suture was
deprived of blood as much as possible and totally devascular-
ized. A second piece of atrium was harvested after termina-
tion of CPB (ischemic group) but before administration of
protamine. Tissue in the pre-CPB (control) and post-CPB
(ischemia) groups was immediately frozen in liquid nitrogen
after harvest in preparation for molecular biology studies or
was placed in cold (5°C-10°C) Krebs buffer solution (118.3
mmol/L NaCl, 4.7 mmol/L KCl, 2.5 mmol/L CaCl2, 1.2
mmol/L MgSO4, 1.2 mmol/L NaH2PO4, 25 mmol/L
NaHCO3, and 11.1 mmol/L glucose) for vascular reactivity
studies. A previous study examining atrial microvessels from
a similar group of patients present the typical clinical pro-
file.14 The study was approved by the clinical research com-
mittee of Beth Israel Deaconess Medical Center.
Messenger RNA analysis by means of reverse tran-
scriptase–polymerase chain reaction. Approximately 1 g of
atrial tissue (n = 16) was snap frozen in liquid nitrogen and
then homogenized and extracted by using TriReagent (Sigma
Chemical Co, St Louis, Mo). The RNA pellet was dissolved
in water and precipitated in ethanol. Complementary DNA
was synthesized for 1.5 hours at 37°C by using 1 µg/20 µL
total RNA, 600 ng/20 µL oligo T20, 10 mmol/L dithiothre-
itol, and 200 units/20 µL M-MLV reverse transcriptase
(Gibco BRL, Life Technologies, Inc, Rockville, Md). For
polymerase chain reaction (PCR), 2.5 U/50 µL RedTaq DNA
Polymerase (Sigma), 1× RedTaq PCR buffer (Sigma), and 2
µL of cDNA were used.
For VEGF mRNA studies, the primers of the sense 5´-
GGATGTCTATCAGCGCAGCTACT -3´, corresponding to
bases 148-170, and the antisense 5´- TCACCGCCTCG-
GCTTGTCACATC -3´, corresponding to bases 570-592,
were used to amplify a 445-base pair fragment of VEGF in 35
cycles (30 seconds at 94°C, 30 seconds at 63°C, and 60 sec-
onds at 72°C). For VEGF receptor 1 (VEGF-R1), the primers
of sense 5´- ACGCCCAGTCAAATTACTTA -3´, corre-
sponding to bases 960-979, and the antisense 5´- TAGAGTG-
GCAGTGAGGTTTT -3´, corresponding to bases 1496-1515,
were used to amplify a 556-base pair fragment of VEGF-R1
in 30 cycles (30 seconds at 94°C, 30 seconds at 56°C, 60 sec-
onds at 72°C). For VEGF receptor 2 (VEGF-R2), the primers
of the sense 5´- AGATAAACCAGGCAACGTAA -3´, corre-
sponding to bases 4737-4756, and the antisense 5´-
AAAGGGTAAAATCCTTCCTG -3´, corresponding to bases
5338-5357, were used to amplify a 621-base pair fragment of
VEGF-R2 in 30 cycles (30 seconds at 94°C, 30 seconds at
56°C, and 60 seconds at 72°C). For FGF2, the primers of the
sense 5´-CAAAGCTTCTCCTTTTCAGA -3´, corresponding
to bases 5881-5900, and the antisense 5´- GAGAAAAG-
GTGGGAAAAGAT -3´, corresponding to bases 6409-6428,
were used to amplify a 548-base pair fragment of FGF2 in 35
cycles (30 seconds at 94°C, 30 seconds at 56°C, and 60 sec-
onds at 72°C). For FGF receptor (FGFR), the primers of the
sense 5´- CAGACTGGTCTTAGGCAAAC -3´, correspond-
ing to bases 1545-1564, and the antisense 5´-
CTTGAAAAGTTCCTCCACAG -3´, corresponding to bases
2231-2250, were used to amplify a 706-base pair fragment of
FGFR in 35 cycles (30 seconds at 94°C, 30 seconds at 56°C,
and 60 seconds at 72°C).
Equal amounts of total RNA were used for reverse tran-
scriptase PCR. For quantification, glyceraldehyde-3-phos-
phate dehydrogenase was amplified from the same amount of
RNA to correct for variation of different samples. The
primers of the sense 5´- ATGGGGAAGGTGAAGGTCGAG
-3´, corresponding to bases 61-82, and the antisense 5´- CTC-
CTTGGAGGCCATGTGGGCCATGAGG -3´, correspond-
ing to bases 1138-1165, were used to amplify a 1105-base
pair fragment of glyceraldehyde-3-phosphate dehydrogenase
in 35 cycles (30 seconds at 94°C, 30 seconds at 63°C, and 60
seconds at 72°C). The PCR products were subjected to elec-
trophoresis on 1.5% agarose gel, scanned, and quantitated by
using Image-Quant software (Molecular Dynamics,
Sunnyvale, Calif).
Protein analysis by using Western blotting. Total protein
from atrial tissues was obtained by homogenation in a lysis
buffer containing 1% NP-40, 0.5% sodium deoxycholate, and
0.1% SDS and centrifuging at 12,000g for 10 minutes at 4°C.
Protein concentration of the supernatant was measured by
using spectrophotometry at 595 nm (DU640, Beckman) of an
aliquot developed for 10 minutes in protein assay dye reagent
(Bio-Rad, Hercules, Calif) with bovine serum albumin (Bio-
Rad) as standard. Total protein (40 µg/lane) was fractionated
on 10% sodium dodecylsulfate–polyacrylamide gel elec-
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trophoresis gel (Bio-Rad) transferred to a polyvinylidene
difluoride membrane (Millipore, Bedford, Mass).
Commassie blue staining of the fractionated gel was used to
correct for variation of protein loading and transfer efficien-
cy of different samples.
The membrane was incubated with 5% nonfat dry milk
powder and 0.05% Tween-20 (Sigma) in Tris-buffered saline
(TBS; 2.42 g of Tris base plus 8 g of NaCl/1000 mL, pH 7.6)
for 1 hour at 4°C to block nonspecific absorption and then
was immunoblotted with the primary antibody at 1:2000 dilu-
tion overnight at 4°C. The primary antibodies for VEGF,
VEGF-R1, VEGF-R2, FGF2, and FGFR-1 were rabbit anti-
VEGF polyclonal immunoglobulin G (IgG), rabbit anti-FLT
polyclonal IgG, rabbit anti-FLK polyclonal IgG, goat anti-
FGF2 polyclonal IgG, and goat anti-FGFR polyclonal IgG
(Santa Cruz Biotechnology, Santa Cruz, Calif), respectively.
After being washed with TBS-T solution (TBS plus 0.05%
Tween-20), the membrane was incubated for 1 hour in 5%
milk powder TBS-T containing 1:2000 diluted anti-rabbit
IgG conjugated to horseradish peroxidase (Vector Lab-
oratories, Burlingame, Calif) or anti-goat IgG conjugated to
horseradish peroxidase (Santa Cruz Biotechnology).
Peroxidase activity was visualized by exposing an x-ray film
to blots incubated with the ECL reagent (Amersham,
Arlington Heights, Ill).
Densitometry of digitized images of immunoprobed mem-
branes was performed by using Image-Quant software
(Molecular Dynamics, Sunnyvale, Calif).
In vitro atrial microvascular studies. Atrial microvessels
(70-156 µm in internal diameter) were dissected by using a
10× to 60× microscope (Olympus Optical, Tokyo, Japan).
Microvessels were placed in a microvessel chamber, cannu-
lated with dual glass micropipettes measuring 40 to 80 µm in
diameter, and secured with 10-0 nylon monofilament sutures
(Ethicon, Inc, Somerville, NJ). Oxygenated (95% oxygen and
5% carbon dioxide) Krebs buffer solution warmed to 37°C
was continuously circulated through the microvessel cham-
ber. The vessels were pressurized to 40 mm Hg in a no-flow
state by using a burette manometer filled with a Krebs buffer
solution. With an inverted microscope (40×-200×; Olympus
CK2, Olympus Optical) connected to a video camera, the
vessel image was projected onto a black and white television
monitor. An electronic dimension analyzer (Living System
Instrumentation, Burlington, Vt) was used to measure the
internal lumen diameter. Vessels were allowed to bathe in the
organ chamber for at least 30 minutes before a pharmacolog-
ic intervention.
Microvessel study protocols. Relaxation responses of
microvessels were examined after development of sponta-
neous tone with or without supplemental precontraction with
the thromboxane A2 analog U46619. Baseline diameter was
defined as the internal diameter within minutes of cannula-
tion and placement in the bath when the diameter tended to
be at a maximum and spontaneous contraction had not yet
occurred. At the completion of an experiment, papaverine
(10–4 mol/L) was applied to confirm that the initial diameter
reading was similar to the maximally dilated diameter. If the
spontaneous contraction was less than 30% of the initial
baseline diameter, incremental concentrations of U46619
(10–8 to 10–6 mol/L) were applied so that the final precon-
traction was 30% to 60% of the initial baseline diameter.
Vascular responses to VEGF (10–16 to 10–10 mol/L), FGF2
(10–16 to 10–10 mol/L), substance P (10–15 to 10–6 mol/L), and
sodium nitroprusside (10–9 to 10–4 mol/L) were examined.
Further experiments were performed in the presence of NG-
nitro-L-arginine (L-NNA; 10–4 mol/L). L-NNA was applied
for 20 minutes before a dose-response intervention was per-
formed. All drugs were applied extraluminally. Measure-
ments were made and recorded 2 to 3 minutes after drug
administration, when the response had stabilized.
In measuring the response to VEGF, it took 5 to 8 minutes
for the response to be stabilized. Once VEGF or substance P
was applied to a vessel, the vessel was discarded to avoid
tachyphylaxis. One to 4 interventions was performed on each
vessel. The order of drug administration was random. The
vessels were washed 3 times with a Krebs buffer solution and
allowed to equilibrate in a drug-free Krebs buffer solution for
15 to 30 minutes between interventions.
Drugs. Human recombinant VEGF and FGF2 were
obtained from Genentech (South San Francisco, Calif).
Substance P was obtained from RBI (Natick, Mass). L-NNA,
U46619, and sodium nitroprusside were obtained from
Sigma Chemical Co. VEGF and FGF2 were dissolved in
phosphate-buffered saline solution with 0.1% bovine serum
albumin to make stock solutions that were stored at –80°C. L-
NNA and sodium nitroprusside were dissolved in ultrapure
distilled water and were stored at –20°C. U46619 was dis-
solved in ethanol to make a 10 mmol/L stock solution that
was stored at –20°C. Dilutions were prepared daily.
Data analysis. The relaxation responses were expressed as
the percentage of relaxation of the spontaneous vascular con-
traction of the microvessels, the U46619-induced contraction
(mean ± SD) of the microvessels, or both. Responses of ves-
sels were compared with one- or two-factor ANOVA for
repeated measures, followed by the Scheffe multiple compar-
ison test. The paired Student t test was used to compare
mRNA and protein expressions between control and ischemic
tissues. Data are shown as means ± SD versus control.
Results
Clinical characteristics of patients. We studied 16
patients (12 male and 4 female patients), with an aver-
age age of 64 ± 12 years. The ischemic time averaged
65 ± 7 minutes. Sixty-nine percent (11/16) of the
patients had hypertension, 19% (3/16) had diabetes
mellitus, and 19% (3/16) had a recent smoking histo-
ry. The total cholesterol level of these patients was
169 ± 42 mg/dL, the triglyceride level was 65 ± 32
mg/dL, the high-density lipoprotein level was 56 ± 2
mg/dL, and the low-density lipoprotein level was 101
± 34 mg/dL. The left ventricular ejection fraction of
these patients averaged 48% ± 12%.
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Induction of VEGF and VEGF-R1 mRNA in acute
ischemic myocardium. The RNA expression was ana-
lyzed by using reverse transcriptase PCR and expressed
as the percentage of density ratio to the control speci-
mens (100% expression in nonischemic control
microvessels) for quantitative analysis. The RNA level
of VEGF and VEGF-R1 was increased by 22.2% ±
4.2% and 30.7% ± 7.6%, respectively (P < .05), in the
ischemic specimens versus the control specimens.
However, the expression of VEGF-R2 (–3.1% ± 3.9%
vs control, P > .05), FGF2 (–6.7% ± 3.3% vs control, P
> .05), and FGFR-1 (–2.8% ± 2.1% vs control, P > .05)
remained unchanged (Fig 1, A and B).
Increased VEGF and VEGF-R1 protein level in
acute ischemic myocardium. To further explore the
changes in VEGF and VEGF-R1 in human ischemic
myocardium, we performed Western blot analysis to
determine whether the increase in VEGF and VEGF-
R1 in mRNA level was associated with an increase in
the level of VEGF protein. The antibodies recognized
VEGF with a molecular mass of 23 kd and VEGF-R1
with a molecular mass of 130 kd. Expression of VEGF
demonstrated an increase of 71.7% ± 27.8% in
ischemic tissue, whereas VEGF-R1 increased 68.2% ±
27.6% in density of protein level. The expression of
another VEGF receptor, VEGF-R2 (46.5% ± 28.7%,
P > .05), as well as that of FGF2 (21.3% ± 14.0%,
P > .05) and FGFR-1 (17.7% ± 15.7%, P > .05), were
not different in protein level between ischemic and
control myocardium (Fig 2, A and B).
Vessel characteristics. Internal diameter of atrial
microvessels ranged from 70 to 156 µm, averaging 118
± 27 µm in the control group and 120 ± 22 µm in the
ischemic group. The percentage of precontraction after
spontaneous constriction or after application of the
thromboxane A2 analog U46619 (1 nmol/L-1 µmol/L)
was 41% ± 9% in the control group and 42% ± 9% in
the ischemic group. The concentrations of U46619
required to produce these degrees of precontraction
were similar in the 2 groups.
In vitro response to VEGF and FGF2. VEGF
caused a potent dilation of atrial microvessels both in
the control group and in the ischemic group. The aver-
age percentage of dilation of microvessels in the
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Fig 1. A, mRNA expression of VEGF and its receptors VEGF-R1 and VEGF-R2, FGF2 and its receptor FGFR-1,
and loading control glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in human atrial tissue from the nonis-
chemic (control) and ischemic groups, as analyzed with reverse transcriptase PCR. Positions and sizes of the PCR
products in base pairs (bp) are shown at the right. B, Quantitative analysis of mRNA level of expression of VEGF,
VEGF-R1, VEGF-R2, FGF2, and FGFR-1 in atrial tissue in the control group (n = 16) and the acute ischemia group
(n = 16) indexed as the percentage of density ratio to control specimens (100% expression in nonischemic
microvessels). Data are expressed as means ± SD. *P < .05 versus control.
BA
ischemic group to VEGF was reduced compared with
that in the control group (P < .05, Fig 3). After treat-
ment of vessels with 10–4 mol/L nitric oxide synthase
inhibitor L-NNA, the VEGF-induced relaxation was
markedly reduced in the nonischemic control vessels,
suggesting that VEGF caused vascular relaxation in
human atrial microvessels largely through the release
of nitric oxide (Table I).
Similarly, FGF2 induced a significant relaxation of
vessels in both groups, but the response in ischemic
vessels was diminished compared with that in nonis-
chemic vessels (P < .05, Fig 4). The FGF2-induced
relaxation was markedly reduced in the presence of the
nitric oxide synthase inhibitor L-NNA (P < .01), indi-
cating that FGF2-induced relaxation is mainly through
the release of nitric oxide (Table I).
In vitro response to substance P. Substance P elicit-
ed a potent relaxation response in atrial arterioles that
was inhibited in the presence of nitric oxide synthase
inhibitor L-NNA (Table I). The relaxation of microves-
sels to substance P was significantly decreased in the
ischemic group compared with that of the nonischemic
vessels, suggesting dysfunctioned endothelium after
ischemia (Fig 5).
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A B
Fig 2. A, Protein expression of VEGF, VEGF-R1, VEGF-R2, FGF2, FGFR-1, and of loading control Commassie
blue in human atrium from the nonischemic (control) and ischemic groups, as analyzed with Western blotting.
Positions and sizes of the blotting bands in kilodaltons are shown at the right. B, Quantitative analysis of protein
expression of VEGF, VEGF-R1, VEGF-R2, FGF2, and FGFR-1 in atrial microvessels in the control (n = 16) and
acute ischemia (n = 16) groups indexed as the percentage of density ratio to control specimens (100% expression
in nonischemic microvessels). Data are expressed as means ± SD. *P < .05 versus control.
Table I. Microvessels relaxation in the presence of NO inhibitor L-NNA
Mean precontraction (%)
L-NNA, 10–4 mol/L (n) Control (n) P value
VEGF (10–11 mol/L) 14.9 ± 8.4 (7) 37.3 ± 16.5 (6) .019
FGF2 (10–11 mol/L) 5.9 ± 3.2 (6) 30.2 ± 9.3 (6) .001
Substance P (10–6 mol/L) 10.0 ± 6.5 (6) 48.1 ± 12.2 (8) .006
Selected experiments were performed on microvessels in the presence of the nitric oxide synthase inhibitor L-NNA. Responses are the percentage of relaxation of
spontaneous contractions, U46619-induced contractions, or both. Values are given as means ± SD.
In vitro response to sodium nitroprusside. The
relaxation of atrial microvessels to sodium nitroprus-
side, which operates through an endothelium-indepen-
dent cyclic guanosine monophosphate–mediated mech-
anism,16,17 was similar in both groups. This suggests
that ischemia causes no alteration of the smooth mus-
cle’s ability to relax through the cyclic guanosine
monophosphate pathway (Fig 6).
Discussion
The new findings of this study are that the expres-
sions of VEGF and VEGF-R1 were increased after a
brief period of acute myocardial ischemia, whereas the
expressions of the VEGF-R2, FGF2, and FGFR-1 were
not increased significantly. Despite the increased
expression of VEGF-R1, the microvascular relaxation
was impaired, most likely as a result of impaired
endothelial function.
Why are these findings potentially important? First,
although it is already well known from studies in rats
that the expression of VEGF and its receptors is
increased in myocardium early after the onset on acute
ischemia,18,19 extrapolating a heightened physiologic
effect may not be justified because VEGF, FGF2, and
several other angiogenic substances may operate
through the stimulated release of nitric oxide by activa-
tion of tyrosine kinase receptors.20-22 Because endothe-
lial dysfunction is known to occur during acute
myocardial ischemia,23-25 it is plausible that the physi-
ologic actions of endogenous growth factors may be
impaired. This was suggested by the findings of this
study. The relaxation responses to VEGF, FGF2, and
the endothelium-dependent vasodilator substance P
were all diminished in the presence of the nitric oxide
synthase inhibitor L-NNA, suggesting that the respons-
es are mediated largely through the release of nitric
oxide, as they are in other species.26,27 The finding that
the endothelium-dependent agonist substance P was
also impaired suggests that acute myocardial ischemia
causes a generalized impairment in endothelial func-
tion, at least as far as vasomotor regulation is con-
cerned. Interestingly, in a recent study in pigs subject-
ed to ameroid constriction of the circumflex coronary
artery,28 the expression of VEGF-R1 and VEGF-R2
was increased, and this was associated with an
increased relaxation response to VEGF and FGF2,
despite impaired endothelium-dependent relaxation to
adenosine 5-diphosphate. Because vessels and atrial
tissue were examined after ischemia alone without
reperfusion, it is suspected that the increased expres-
sion of VEGF and VEGF-R1 may actually underesti-
mate the expression one would encounter after
ischemia and reperfusion.
Second, the physiologic effect of the delivery of
angiogenic growth factors in patients has generally
been disappointing, especially when compared with the
marked affect in otherwise normal pigs with chronic
myocardial ischemia.29-32 This diminished effect may
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Fig 3. Plot of in vitro response of atrial microvessels to
VEGF in the control group (n = 7) and the acute ischemia
group (n = 8). Responses are percentage of relaxation of
spontaneous contractions, U46619-induced contractions, or
both. Data are expressed as mean ± SD. *P < .05 versus con-
trol.
Fig 4. Plot of in vitro response of atrial microvessels to FGF2
in the control group (n = 8) and the acute ischemia group 
(n = 8). Responses are percentage of relaxation of sponta-
neous contractions, U46619-induced contractions, or both.
Data are expressed as means ± SD. *P < .05 versus control.
be due to impaired endothelium function because
endothelial dysfunction is observed in patients after
acute or chronic myocardial ischemia, atherosclerosis,
diabetes mellitus, hypertension, and other factors asso-
ciated with coronary artery disease. Because the effec-
tiveness of the growth factors is associated with the
release of nitric oxide, endothelial dysfunction may
diminish the effectiveness of these growth factors. Thus
the increased receptor expression may not translate into
a heightened physiologic action because of receptor
inactivity or a defect in other levels of signal transduc-
tion or in nitric oxide synthesis. One limitation of the
study is that atrial, rather than ventricular, myocardium
was used. Although there are many similarities
between these tissues, it cannot be concluded with cer-
tainty that identical results would be observed had ven-
tricular myocardium been examined. Furthermore,
although the atrial tissue was surrounded by a silk
suture and devascularized as much as possible, this tis-
sue may have been exposed to inflammatory mediators,
such as cytokines, from a small amount of blood either
from the surface or through the vasculature. Thus it
cannot be concluded that these cytokine and other
inflammatory mediators did not play a small role in the
changes observed.
In summary, the expression of VEGF and one of its
receptors was increased in acute myocardial ischemia in
patients. However, the expression of FGF2 and FGFR-1
was unchanged, and the vascular responses to VEGF and
FGF2 were impaired. These findings may not only have
implications regarding the mechanism of coronary collat-
eral development after acute coronary occlusion but may
also affect the efficacy of therapeutic angiogenesis with
angiogenic growth factors or genes encoding the growth
factors for the treatment of patients with coronary occlu-
sive disease not amenable to treatment with angioplasty
or coronary artery bypass grafting.
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